Showing 2581-2590 of 2652 results for "".
- Novaliq Raises New Capital to Accelerate the Commercialization of its Lead Products for Dry Eye Diseasehttps://modernod.com/news/novaliq-raises-new-capital-to-accelerate-the-commercialization-of-its-lead-products-for-dry-eye-disease/2479793/Novaliq announced it has raised $53 million to further support its late-stage products and earlier pipeline programs. Since inception, Novaliq has raised $115 million. The new investment is done by its lead investor dievini Hopp BioTech Holding, an active investor in Life and Health Scienc
- Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Dayhttps://modernod.com/news/johnson-johnson-vision-launches-worldwide-campaign-to-spotlightsight-in-honor-of-world-sight-day/2479805/Sight is the most prized of all human senses. Yet, there are many people who do not fully experience the wonder of this gift. Nearly 285 million people around the world face impaired vision, and 80 percent of those cases are preventable with early diagnosis and treatment. That’s why Johnson
- Department of Defense Grant for Clinical Trial of Stem Cell Therapy for Eye Injurieshttps://modernod.com/news/department-of-defense-grant-for-clinical-trial-of-stem-cell-therapy-for-eye-injuries/2479809/Researchers at the University of Illinois at Chicago have received a 4-year, $5.25 million grant from the U.S. Department of Defense to lead a multisite clinical trial to test the efficacy of a stem cell-based treatment for eye injuries. The treatment uses mesenchymal stem cells—cells that
- Neurolens Appoints Davis Corley Chief Executive Officerhttps://modernod.com/news/neurolens-appoints-davis-corley-chief-executive-officer/2479848/Neurolens announced that its board of directors has named Davis Corley chief executive officer (CEO). Mr. Corley was a co-founder of neurolens in 2012 and has served as president since 2014, a role that he will continue. “Since day one, Davis has led the dev
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site
- Heidelberg Engineering Announces CE Mark Approval of Anterionhttps://modernod.com/news/heidelberg-engineering-announces-the-ce-marking-of-anterion/2479854/Heidelberg Engineering announced the CE-marking of Anterion, a platform designed to transform anterior segment diagnostics and workflow. The new Anterion provides anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solutio
- Optos Launches Monaco Ultra-Widefield Retinal Imaging Systemhttps://modernod.com/news/optos-launches-monaco-ultra-widefield-retinal-imaging-system/2479855/Optos has launched Monaco, its latest ultra-widefield device to the European ophthalmic market. Monaco is the only ultra-widefield retinal imaging system with integrated Optical Coherence Tomography (OCT), according to Optos. It produces a 200° single-capture optomap image in less than hal
- Oxurion Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-enrolls-first-patient-in-phase-1-clinical-trial-evaluating-thr-687-for-treatment-of-dme/2479860/Oxurion announced the enrollment of the first patient in a phase 1 open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with diabetic macula edema (DME). THR-687 is a novel pan-RGD integrin antagoni
- Oculis Elects Anthony Rosenberg and David A. Weber to Its Board of Directorshttps://modernod.com/news/oculis-elects-anthony-rosenberg-and-david-a-weber-to-its-board-of-directors/2479867/Oculis announced the appointments of Anthony Rosenberg as Non-Executive Chairman and David A. Weber, PhD, as Non-Executive Director. Together, they bring more than 60 years’ experience from the global pharmaceutical and eye care industries to the compa
- Chinese Regulators Clear Takeda’s $62-Billion Takeover of Shirehttps://modernod.com/news/chinese-regulators-clear-takedas-62-billion-takeover-of-shire/2479882/Takeda said that China’s State Administration for Market Regulation has granted unconditional approval of its proposed $62-billion purchase of Shire. The Japanese drugmaker expects to complete the transaction in the first half of next year. China’s regulatory clearance “